TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Nvidia's Gaming Transition Spells an Opportunity for Patient Investors
JIM CRAMER

Nvidia, Microsoft, Kimberly-Clark: 'Mad Money' Lightning Round

  • By Scott Rutt
  • Jan 22, 2019 8:40 PM EST
PRESS RELEASES

Ligand Announces Clinical And Regulatory Progress By Multiple Partners With OmniAb® Antibodies

  • By Business Wire
  • Nov 23, 2020 8:30 AM EST
PRESS RELEASES

Ligand's Captisol Technology Plays Key Role In The Manufacture Of Gilead's Veklury, The First FDA-Approved COVID-19 Treatment

  • By Business Wire
  • Oct 23, 2020 8:30 AM EDT
PRESS RELEASES

Ligand Provides Highlights From Today's Investor Day Event

  • By Business Wire
  • Oct 20, 2020 2:05 PM EDT
PRESS RELEASES

Ligand To Divest Vernalis Research Operations

  • By Business Wire
  • Oct 12, 2020 9:00 AM EDT
PRESS RELEASES

Ligand To Host Virtual Investor Day On October 20th

  • By Business Wire
  • Oct 2, 2020 8:00 AM EDT
PRESS RELEASES

Ligand Announces Expiration Of Tender Offer For Shares Of Pfenex Inc.

  • By Business Wire
  • Sep 30, 2020 8:00 AM EDT
PRESS RELEASES

Ligand Expands OmniAb® Antibody Discovery Platform Through The Acquisitions Of XCella Biosciences And Taurus Biosciences

  • By Business Wire
  • Sep 10, 2020 8:00 AM EDT
PRESS RELEASES

Ligand Pharmaceuticals Management To Present At The H.C. Wainwright 22nd Annual Global Investment Virtual Conference

  • By Business Wire
  • Sep 1, 2020 4:02 PM EDT
PRESS RELEASES

Ligand Commences Previously Announced Cash Tender Offer To Acquire Pfenex Inc.

  • By Business Wire
  • Aug 31, 2020 9:00 AM EDT
PRESS RELEASES

Ligand OmniAb® Partner Immunovant Announced Positive Topline Results From Multicenter, Placebo-Controlled Phase 2a Trial Of IMVT-1401 In Myasthenia Gravis

  • By Business Wire
  • Aug 25, 2020 4:15 PM EDT
PRESS RELEASES

Ligand Announces Amgen's KYPROLIS® Approved By FDA As Combination Regimen With DARZALEX® And Dexamethasone In Once- And Twice-Weekly Dosing Regimens For Patients With Relapsed/Refractory Multiple Myeloma

  • By Business Wire
  • Aug 24, 2020 8:30 AM EDT
PRESS RELEASES

SHAREHOLDER ALERT: WeissLaw LLP Investigates Pfenex, Inc.

  • By PR Newswire
  • Aug 11, 2020 9:05 PM EDT
PRESS RELEASES

PFENEX ALERT: Bragar Eagel & Squire, P.C. Investigates Sale Of PFNX And Encourages Investors To Contact The Firm

  • By Business Wire
  • Aug 10, 2020 8:40 PM EDT
PRESS RELEASES

Ligand To Acquire Pfenex Inc.

  • By Business Wire
  • Aug 10, 2020 5:36 PM EDT
PRESS RELEASES

Functional, Human Antibodies Targeting SARS-CoV-2 Discovered Using IPA's Proprietary B Cell Select™ And Single Step Cloning Hybridoma Technologies

  • By PR Newswire
  • Jul 13, 2020 7:51 AM EDT
PRESS RELEASES

IPA Confirms Discovery Of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2

  • By PR Newswire
  • Jun 29, 2020 12:48 PM EDT
PRESS RELEASES

Ligand Announces An Expansion Of Vernalis Collaboration With Servier For Research On Novel Oncology Targets

  • By Business Wire
  • Jun 15, 2020 8:30 AM EDT
PRESS RELEASES

Ligand CEO Issues Letter To Captisol Customers

  • By Business Wire
  • Jun 1, 2020 4:53 PM EDT
PRESS RELEASES

Ligand Announces Icagen's Expansion Of Collaboration With Roche To Develop And Commercialize Therapies For Neurological Diseases

  • By Business Wire
  • May 29, 2020 8:00 AM EDT
PRESS RELEASES

Ligand Earns $3 Million Milestone Payment From Palvella Therapeutics

  • By Business Wire
  • May 28, 2020 4:22 PM EDT
PRESS RELEASES

ImmunoPrecise Provides Updates On B Cell Select™ And Deep Display™ Programs For SARS-CoV-2 Antibody Discovery

  • By PR Newswire
  • Apr 17, 2020 8:00 AM EDT
PRESS RELEASES

Ligand Provides A Corporate Update And Announces May 6th As The Date For First Quarter Earnings Call

  • By Business Wire
  • Apr 6, 2020 7:00 AM EDT
PRESS RELEASES

Ligand Completes Acquisition Of Icagen Core Assets, Partnered Programs And Ion Channel Technologies

  • By Business Wire
  • Apr 2, 2020 4:02 PM EDT
PRESS RELEASES

Ligand's Presentation At The Barclays Global Healthcare Conference Now A Webcast Only, New Slides Available On Ligand.com

  • By Business Wire
  • Mar 10, 2020 8:00 AM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.